Lataa...
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML
Bcr-abl kinase inhibitors have provided proof of principal that targeted therapy holds great promise for the treatment of cancer. However, despite the success of these agents in treating chronic myelogenous leukemia (CML), the majority of patients continue to present with minimal residual disease co...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3285111/ https://ncbi.nlm.nih.gov/pubmed/20382130 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2010.04.003 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|